Skip to main content
Reem Karmali, MD, Oncology, Chicago, IL

ReemKarmaliMD

Oncology Chicago, IL

Hematologic Oncology

Associate Professor, Division of Hematology/ Oncology, Northwestern University Feinberg School of Medicine, Robert H Lurie Cancer Center

Dr. Karmali is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Karmali's full profile

Already have an account?

  • Office

    676 N Saint Clair St
    Ste 850
    Chicago, IL 60611
    Phone+1 312-695-0990
    Fax+1 312-695-1106

Summary

  • Dr. Reem Karmali is an oncologist in Chicago, IL and is affiliated with Northwestern Memorial Hospital. She received her medical degree from University of Western Ontario and has been in practice 11 years. She specializes in hematologic oncology.

Education & Training

  • Rush University Medical Center
    Rush University Medical CenterFellowship, Hematology and Medical Oncology, 2012
  • Rush University Medical Center
    Rush University Medical CenterResidency, Internal Medicine, 2009
  • University of Western Ontario
    University of Western OntarioClass of 2006

Certifications & Licensure

  • IL State Medical License
    IL State Medical License 2009 - 2026
  • American Board of Internal Medicine Hematology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Outcomes Following Early Relapse in Patients with Mantle Cell Lymphoma
    Reem Karmali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Impact of Novel Agents on Outcomes of Patients with Classical Hodgkin Lymphoma and Primary Treatment Failure
    Reem Karmali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • A Phase I/II Trial of Brentuximab Vedotin (BV) Plus Rituximab (R) As Frontline Therapy for Patients with Immunosuppression-Associated CD30+ and/or EBV+ Lymphomas
    Reem Karmali, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • Ibrutinib maintenance following induction for untreated mantle cell lymphoma (MCL): Initial safety report. 
    2019 ASCO Annual Meeting - 6/1/2019
  • Ibrutinib Maintenance (I-M) Following Frontline Intensive Induction in Mantle Cell Lymphoma (MCL): Interim Safety, Response and Sequential MRD Evaluation 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • Exploring CAR T-cell Therapy for Aggressive Follicular Lymphoma
    Exploring CAR T-cell Therapy for Aggressive Follicular LymphomaJuly 18th, 2024
  • Confronting Knowledge Gaps Concerning Relapsed/Refractory Follicular Lymphoma
    Confronting Knowledge Gaps Concerning Relapsed/Refractory Follicular LymphomaJune 22nd, 2022
  • Dr. Karmali on Challenges in MCL
    Dr. Karmali on Challenges in MCLJuly 10th, 2019
  • Join now to see all